A carregar...
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PeerJ Inc.
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3628892/ https://ncbi.nlm.nih.gov/pubmed/23638367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7717/peerj.31 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|